Inventor
MAXEY KIRK M
US16 patents
⚠️ This page may combine multiple inventors who share the name “MAXEY KIRK M”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CAYMAN CHEMICAL CO INC
7 patentsUS9487478B2Nov 8, 2016
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC4 citations82
US9180116B2Nov 10, 2015
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC6 citations82
US11884624B2Jan 30, 2024
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC0 citations61
US11066361B2Jul 20, 2021
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC0 citations61
US10556862B2Feb 11, 2020
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC0 citations49
US9676712B2Jun 13, 2017
Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC0 citations39
US9688627B2Jun 27, 2017
Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC0 citations38
CAYMAN CHEM CO
3 patentsUS7674921B2Mar 9, 2010
Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension
CAYMAN CHEM CO4 citations56
US7358275B2Apr 15, 2008
Internal 1,15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension
CAYMAN CHEM CO2 citations56
US7585889B2Sep 8, 2009
Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension
CAYMAN CHEM CO0 citations45